Algert Global LLC Raises Stock Holdings in Guardant Health, Inc. $GH

Algert Global LLC raised its stake in Guardant Health, Inc. (NASDAQ:GH) by 169.1% during the third quarter, HoldingsChannel reports. The institutional investor owned 120,114 shares of the company’s stock after purchasing an additional 75,474 shares during the quarter. Algert Global LLC’s holdings in Guardant Health were worth $7,505,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the stock. Emerald Advisers LLC increased its holdings in Guardant Health by 24.8% in the 3rd quarter. Emerald Advisers LLC now owns 873,203 shares of the company’s stock valued at $54,558,000 after purchasing an additional 173,281 shares during the last quarter. Knights of Columbus Asset Advisors LLC acquired a new position in Guardant Health during the third quarter worth $1,554,000. Edgestream Partners L.P. lifted its stake in Guardant Health by 147.3% during the second quarter. Edgestream Partners L.P. now owns 50,519 shares of the company’s stock worth $2,629,000 after purchasing an additional 30,094 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH boosted its position in shares of Guardant Health by 54.4% during the third quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 301,449 shares of the company’s stock worth $18,835,000 after buying an additional 106,263 shares during the period. Finally, State of Wyoming purchased a new position in shares of Guardant Health during the second quarter worth $567,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Insider Activity

In other news, Director Medina Manuel Hidalgo sold 1,300 shares of Guardant Health stock in a transaction dated Friday, March 6th. The stock was sold at an average price of $91.54, for a total value of $119,002.00. Following the completion of the transaction, the director owned 1,193 shares in the company, valued at approximately $109,207.22. This trade represents a 52.15% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Terilyn J. Monroe sold 10,031 shares of the business’s stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $112.08, for a total value of $1,124,274.48. Following the transaction, the insider directly owned 20,990 shares of the company’s stock, valued at approximately $2,352,559.20. This represents a 32.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 20,018 shares of company stock valued at $2,232,911 in the last quarter. Company insiders own 6.10% of the company’s stock.

Guardant Health Trading Up 2.0%

Shares of NASDAQ GH opened at $87.18 on Tuesday. The stock has a market cap of $11.44 billion, a P/E ratio of -26.34 and a beta of 1.67. The business’s fifty day simple moving average is $103.62 and its 200-day simple moving average is $90.18. Guardant Health, Inc. has a 12-month low of $36.36 and a 12-month high of $120.74.

Guardant Health (NASDAQ:GH) last released its earnings results on Thursday, February 19th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.07). The company had revenue of $281.27 million during the quarter, compared to analysts’ expectations of $269.74 million. During the same period last year, the firm earned ($0.62) earnings per share. Guardant Health’s quarterly revenue was up 39.4% compared to the same quarter last year. On average, equities analysts forecast that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. Wells Fargo & Company boosted their price objective on Guardant Health from $120.00 to $125.00 and gave the company an “overweight” rating in a report on Friday, February 20th. BTIG Research raised their target price on Guardant Health from $140.00 to $145.00 and gave the company a “buy” rating in a report on Friday, February 20th. Guggenheim lifted their target price on Guardant Health from $115.00 to $135.00 and gave the company a “buy” rating in a research report on Monday, January 26th. TD Cowen boosted their price target on shares of Guardant Health from $130.00 to $135.00 and gave the stock a “buy” rating in a research note on Friday, February 20th. Finally, Evercore set a $110.00 price target on shares of Guardant Health in a research report on Friday, February 20th. Twenty-one investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Guardant Health currently has a consensus rating of “Moderate Buy” and an average target price of $122.57.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.